Parecoxib

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Selective cyclooxygenase inhibitor (COX-2 inhibitor), which is considered a perioperative alternative to mixed NSAIDs (e.g. diclofenac or others). Parecoxib has no ulcerogenic effect and does not inhibit platelet aggregation.

IndicationThis section has been translated automatically.

For short-term treatment of post-operative pain.

Pregnancy/nursing periodThis section has been translated automatically.

Contraindicated in the 3rd trimester (risk of weakness in labour and premature closure of the Botalli duct). Strictest examination of the indication in the 1st and 2nd trimester (insufficient data, no adequate and well-controlled studies available!) Do not use in the lactation period!

Dosage and method of useThis section has been translated automatically.

Initial 40 mg i.v. or i.m., add 20 mg or 40 mg i.v. or i.m. every 6-12 hours as required. Maximum daily dose: 80 mg.

Notice! Dose adjustment necessary in older patients (≥ 65 yrs.), especially with a weight < 50 kg KG and with liver dysfunction!

Undesirable effectsThis section has been translated automatically.

Among others, hypertension, hypotension, back pain, peripheral edema, hypaesthesia, alveolar osteitis, dyspepsia, flatulence, creatinine increase, hypokalemia, agitation, insomnia, pharyngitis, pruritus, oliguria.

InteractionsThis section has been translated automatically.

Oral anticoagulants (phenprocoumon, warfarin): Increased risk of bleeding. Reduced effectiveness of diuretics and antihypertensives. ACE inhibitors/diuretics: Risk of acute renal failure. Ciclosporin A and Tacrolimus: increase in nephrotoxic effects of Ciclosporin and Tacrolimus.

ContraindicationThis section has been translated automatically.

Cave!

Sulfamide allergy! Adverse drug reaction after ingestion of acetylsalicylic acid, COX-2 inhibitors or other NSAIDs, active peptic ulcers, gastrointestinal bleeding, inflammatory bowel disease, severe decompensated heart failure, severe liver dysfunction.

Notice! Do not use on children!

PreparationsThis section has been translated automatically.

Dynasty

LiteratureThis section has been translated automatically.

  1. Capone ML et al (2003) Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 16(2 Suppl): 49-58
  2. Joshi GP et al (2004) Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth Analg 98: 336-342
  3. Malan TP Jr et al (2003) Parecoxib sodium, a parenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology 98: 950-956
  4. Mehlisch DR et al (2003) Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. J Oral Maxillofac Surgery 61: 1030-1037
  5. Smith HS et al (2003) Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population. At J Hosp Palliat Care 20: 297-306

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer